- Date2024-09-06
Publication of Review Result of the First Pharmaceutical Reimbursement Evaluation Committee of 2023
□ The Health Insurance Review and Assessment Service (President Kim Sun-min) releases the results of the deliberations of the 1st Pharmaceutical Reimbursement Evaluation Committee in 2023 as follows.
○ Result of the review of the adequacy of the healthcare benefit for the pharmaceutical applied for assessment
Product Pharmaceutical company Efficacy and effectiveness Deliberation results Dupixent Pre-filled Inj. 200, 300mg (Duplizumab, Recombinant DNA) Sanofi Aventis Korea, Inc. 1. Atopic dermatitis 2. Asthma Chronic rhinosinusitis [1. Atopic dermatitis in children and adolescents]. Reimbursement is adequate.
※ Pursuant to Article 11(2) of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service evaluates the adequacy of reimbursement for drugs after deliberation by the Pharmaceutical Reimbursement Evaluation Committee. The final evaluation results may be subject to change if there are changes in the detailed reimbursement scope and items of the drug, changes in the approval of the item applied for decision, or revocation (cancellation) of the approval.
